Qazi Shurjeel Uddin, Ansari Huzaifa Ul Haq, Tharwani Zoaib Habib, Altaf Zahabia, Noman Ayesha, Ghazanfar Shamas, Kumar Sangeet, Ansari Haya Waseem, Nasir Muhammad Moiz, Qazi Sana
Dow University of Health Sciences, Karachi, Pakistan.
Liaquat National Hospital, Karachi, Pakistan.
J Diabetes Metab Disord. 2024 Mar 18;23(1):405-415. doi: 10.1007/s40200-024-01409-3. eCollection 2024 Jun.
Efpeglenatide, a novel GLP-1 receptor agonist, has shown promise in improving glycemic control and inducing weight loss in individuals with type 2 diabetes (T2DM). This meta-analysis assessed its therapeutic potential and safety profile.
A literature search was conducted on PubMed, SCOPUS, and Cochrane Central from inception until September 2023. We selected patients with T2DM and identified and compared those receiving efpeglenatide to placebo. Outcomes assessed included fasting plasma glucose (FPG), HbA1c, body weight, BMI, and cardiometabolic parameters. Data were analyzed using a random-effects model, with results presented as mean differences (MD) for continuous outcomes and risk ratios (RR) for safety analysis, along with their respective 95% confidence intervals. Quality assessment was conducted using the Cochrane risk of bias tool.
We included 11 studies in our analysis. Efpeglenatide demonstrated significant reductions in FPG (MD = -1.53 mmol/L, 95% CI = [-2.86, -0.66], < 0.01), HbA1c (MD = -0.84, 95% CI= [-1.08, -0.60], < 0.01), body weight (MD = -2.24 kg, 95% CI = [-4.20, -2.00], < 0.01), and BMI (MD = -1.61 kg/m, 95% CI= [-2.12, -1.09], < 0.01). However, efpeglenatide was associated with a moderate increase in the risk of gastrointestinal adverse events, nausea, diarrhea, and vomiting. There was a non-significant elevated risk of hypoglycemia.
Efpeglenatide significantly improves glycemic outcomes and promotes weight loss in individuals with diabetes. However, it is associated with moderate adverse effects related to the gastrointestinal system. Thus, further trials are warranted to comprehensively assess its safety and efficacy to derive a robust conclusion.
The online version contains supplementary material available at 10.1007/s40200-024-01409-3.
艾弗格列奈肽是一种新型胰高血糖素样肽-1（GLP-1）受体激动剂，在改善2型糖尿病（T2DM）患者的血糖控制和诱导体重减轻方面已显示出前景。本荟萃分析评估了其治疗潜力和安全性。
在PubMed、SCOPUS和Cochrane Central数据库中从建库至2023年9月进行文献检索。我们选择了T2DM患者，并识别和比较接受艾弗格列奈肽治疗的患者与接受安慰剂治疗的患者。评估的结局包括空腹血糖（FPG）、糖化血红蛋白（HbA1c）、体重、体重指数（BMI）和心脏代谢参数。数据采用随机效应模型进行分析，连续结局的结果以平均差（MD）表示，安全性分析的结果以风险比（RR）表示，并给出各自的95%置信区间。使用Cochrane偏倚风险工具进行质量评估。
我们的分析纳入了11项研究。艾弗格列奈肽显著降低了FPG（MD = -1.53 mmol/L，95%CI = [-2.86, -0.66]，P < 0.01）、HbA1c（MD = -0.84，95%CI = [-1.08, -I.60]，P < 0.01）、体重（MD = -2.24 kg，95%CI = [-4.20, -0.20]，P < 0.01）和BMI（MD = -1.61 kg/m²，95%CI = [-2.12, -1.09]，P < 0.01）。然而，艾弗格列奈肽与胃肠道不良事件、恶心、腹泻和呕吐风险的中度增加相关。低血糖风险有非显著性升高。
艾弗格列奈肽显著改善糖尿病患者的血糖结局并促进体重减轻。然而，它与胃肠道系统相关的中度不良反应有关。因此，有必要进行进一步试验以全面评估其安全性和疗效，从而得出可靠结论。
在线版本包含可在10.1007/s40200-024-01409-3获取的补充材料。
